期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺表面活性物质联合沐舒坦治疗早产儿肺透明膜病23例的临床分析

下载PDF
导出
作者 陈雄
机构地区 广西北海市妇幼保健院儿科
出处 《广西医学》 CAS 2008年第8期1232-1233,共2页 Guangxi Medical Journal
关键词 肺透明膜病 早产儿 肺表面活性物质 沐舒坦
分类号 R722 [医药卫生—儿科]
  • 相关文献

参考文献9

  • 1陈超,金汉珍,樊绍曾,邵肖梅,周蓓华,励晓东,栾晓丽,张旭东,姚明珠.肺表面活性物质治疗新生儿呼吸窘迫综合征[J].中华儿科杂志,1994,32(1):9-12. 被引量：27
  • 2张树英.产前用地塞米松预防早产儿肺透明膜病163例临床分析[J].广西医学,2004,26(6):827-828. 被引量：8
  • 3Morley CJ. Surfactant treatment for Premature babies-arevien of clinical trials[ J]. Arch Dis Child,1991,66(4) :445 -450.
  • 4Gaetani P, Silvani V, Butti G, et al. Nitrosourea derivatives induced pulmonary toxicity in patients treated for malignant brain tumors Early subclinical detection and its prevention [ J ]. Eur J Clin Oncol, 1987,23(5) :267 -271.
  • 5Wauer RR,Schmalish G, Bohme B,et al, Randomized doublind trial of Ambroxol for the theatment of respiratory distress syndrome [ J ]. Eur Pediatr, 1992,151 (5) :357 - 363.
  • 6Gillissen A, NoWak D. Characterization of N-acetylcysteine and ambroxol in anti-oxrdant therapy[J]. Respir Med,1998,92(4) :609 -623.
  • 7朱科明,邓小明.沐舒坦对呼吸系统的保护作用及机制[J].上海医学,2000,23(10):637-639. 被引量：339
  • 8Vallsi Soler A, Paramo Andres S, Femandez-Ruanova B,et al. Prenatal corticosteroid and early surfactant therapy in infants born at < or = 30 weeks gestation[J]. An Pediatr (Bare),2004,61(2):118 -123.
  • 9Sinn JK,Ward MC ,Henderson-Smart DJ. Developmental outcome of preterm infants after surfactant therapy: systematic review of randomized controlled trials[J].J Paediatr Child Health,2002,38(6):597-600.

二级参考文献15

  • 1杨弘伟,印学蕾.与早产儿肺透明膜病相关的发病因素分析[J].上海预防医学,2000,12(6):263-264. 被引量：18
  • 2[1]Gillissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med, 1998, 92:609-623.
  • 3[2]Teramoto S, Suzuki M, Ohga E, et al. Effects of ambroxol on spontaneous or stimulated generation of reactive oxygen species by bronchoalveolar lavage cells harvested from patients with or with-out chronic obstructive pulmonary diseases. Pharmacology,1999, 59:135-141.
  • 4[3]Gillissen A, Bartling A, Schoen S, et al. Antioxidant function of ambroxol in mononuclear and polymorphonuclear cells in vitro. Lung, 1997, 175:235-242.
  • 5[4]Park NH, Han ES, Lee CS, et al. The inhibitory effect of ambroxol on respiratory burst, de granulation and cytosolic Ca2+ change in degraded immunoglobulin G-activated neutrophils. Pharmacol Toxicol, 1999, 84: 81-87.
  • 6[5]Pfeifer S, Zissel G, Kienast K, et al. Reduction of cytokine release of blood and bronchoalveolar mononuclear cells by ambroxol. EurJ Med Res, 1997, 2:129-132.
  • 7[6]Stettner S, Ledwozyw A. The effect of Ambroxol on bleomycininduced changes in phospholipid composition of rat lung surfactant. Acta Physiol Hung, 1995, 83:181-187.
  • 8[7]Mira E, Benazzo M, De Paoli F, et al. Surfactants of the air-ways. Critical review and personal research. Acta Otorhinolaryngol Ital, 1997, 17(1 Suppl 56):3-16.
  • 9[8]Nemcekova E, Nosalova G, Franova S. Ambroxol and protective reflexes of the respiratory tract. Bratisl Lek Listy, 1998, 99:111-115.
  • 10[9]Tyrakowski T, Greczko Ⅰ, Sedlaczek A, et al. Electrophysiological investigation of the effects of ambroxol on the transepithelial Na + ion transport pathway in airways. Pol J Pharmacol,1998, 50:31-38.

共引文献370

广西医学
2008年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部